Suggestions
David Ku, MD
VP Corporate Development @ Jasper Therapeutics
Professional Background
Dr. David Ku is a renowned medical professional currently serving as the Vice President of Corporate Development, Portfolio Strategy, and Management at Jasper Therapeutics, an innovative biotechnology company at the forefront of hematopoietic stem cell therapies. With a strategic mindset and extensive experience in the biopharmaceutical sector, Dr. Ku's contributions to the industry, particularly through his leadership role at Jasper, are noteworthy. At Jasper Therapeutics, he leads corporate development initiatives and is also the program lead for briquilimab, a c-Kit targeting antibody. This role places him at the intersection of scientific innovation and strategic business development, showcasing his ability to navigate both the medical and corporate landscapes effectively.
Prior to his pivotal role at Jasper, Dr. Ku was the Director of Strategic Planning at Gilead Sciences, a global leader in biopharmaceuticals. His tenure involved overseeing crucial planning strategies that aligned Gilead's ambitious research and development goals with the broader objectives of the healthcare market. Notably, he served as Engagement Manager at McKinsey & Company's Pharmaceutical and Medical Products Practice, where he delivered impactful consulting services to biopharma companies, focusing on R&D strategies, portfolio management, and mergers and acquisitions.
Education and Achievements
Dr. Ku's academic journey reflects a strong foundation in both medicine and technology, equipping him with a unique set of skills that enhance his contributions to the biotechnology industry. He earned his Doctor of Medicine (MD) degree with distinction from the Icahn School of Medicine at Mount Sinai, a prestigious institution known for its focus on research and innovation in medical education. His academic excellence set the stage for his impressive career in biotechnology and pharmaceuticals.
In addition to his medical degree, Dr. Ku holds a Bachelor of Science (S.B.) in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT). This combination of technical knowledge and medical training enables him to implement cutting-edge technologies and strategies in the development of life-saving therapies. His experiences during his time at MIT, particularly with the High-Throughput Neurotechnology Group, cultivated his skills in applying engineering principles to biological research, fostering a holistic approach to the challenges faced within the biopharmaceutical landscape.
Notable Achievements
Dr. Ku's career is marked by several significant achievements that highlight his expertise in strategic planning and corporate development. At Jasper Therapeutics, he has influenced the company's strategic direction through innovative approaches in portfolio management. His leadership in the briquilimab program has been essential in advancing therapy options for patients with hematopoietic disorders, demonstrating his commitment to translating scientific research into viable treatment solutions.
Before joining Jasper, Dr. Ku played instrumental roles at Gilead Sciences and McKinsey & Company, where he was pivotal in shaping corporate strategies that resulted in successful product development and market positioning. His experience in strategic planning at Gilead is particularly notable, as he helped guide the organization's initiatives in expanding its global reach and impact on human health.
At McKinsey, Dr. Ku's engagement with high-profile biopharma clients allowed him to refine his skills in managing complex projects that integrate research, market analytics, and financial viability. This experience has provided him with insight into the multifaceted challenges organizations face in an ever-evolving healthcare landscape.
Dr. Ku's proficiency in aligning medical advancements with corporate strategies illustrates his exceptional ability to bridge the gap between science, technology, and business, which is increasingly necessary in today's healthcare environment.